Comparison of Lafutidine and Rabeprazole in 7-day Second-line Amoxicillin- and Metronidazole-Containing Triple Therapy for Helicobacter pylori: A Pilot Study

Helicobacter

Volumn 17, Issue 4, 2012, Pages 277-281

  Kudo, Takahiko ^a   Fujinami, Haruka ^a   Ando, Takayuki ^a   Nishikawa, Jun ^a   Ogawa, Kohei ^a   Hosokawa, Ayumu ^a   Orihara, Tadahiro ^a   Murakami, Jun ^a   Takahara, Terumi ^a   Sugiyama, Toshiro ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Helicobacter pylori infection; Lafutidine; Second line therapy

Indexed keywords

AMOXICILLIN; CARBON 13; CLARITHROMYCIN; LAFUTIDINE; METRONIDAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BLOATING; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; DUODENUM ULCER; ERADICATION THERAPY; FEMALE; FLATULENCE; GASTRODUODENAL ULCER; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PILOT STUDY; PRIORITY JOURNAL; SOFT STOOL; STOMACH BIOPSY; STOMACH ULCER; TREATMENT DURATION; TREATMENT RESPONSE; UREA BREATH TEST;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ACETAMIDES; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PILOT PROJECTS; PIPERIDINES; PYRIDINES; TIME FACTORS; YOUNG ADULT;

HELICOBACTER PYLORI;

EID: 84863573387     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2012.00943.x     Document Type: Article

References (26)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-86.
2. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
3. Kudo T, Lu H, Wu JY, Ohno T, Wu MJ, Genta RM, Graham DY, Yamaoka Y. Pattern of transcription factor activation in Helicobacter pylori-infected Mongolian gerbils. Gastroenterology 2007;132:1024-38.
4. Graham DY, Lew GM, Evans DG, Evans DJ Jr, Klein PD. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. Ann Intern Med 1991;115:266-9.
5. Asaka M, Sugiyama T, Kato M, et al. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 2001;6:254-61.
6. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392-7.
7. Kuwayama H, Asaka M, Sugiyama T, Fukuda Y, Aoyama N, Hirai Y, Fujioka T, Japan Rabeprazole Study Group. Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan. Aliment Pharmacol Ther 2007;25:1105-13.
8. Onodera S, Shibata M, Tanaka M, Inaba N, Arai Y, Aoyama M, Lee B, Yamaura T. Gastroprotective mechanism of lafutidine, a novel anti-ulcer drug with histamine H2-receptor antagonistic activity. Arzneimittelforschung 1999;49:519-26.
9. Hagiwara T, Kato M, Anbo T, et al. Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H. pylori infection. World J Gastroenterol 2007;13:3836-40.
10. Inamori M, Togawa J, Iwasaki T, et al. Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use? J Gastroenterol 2005;40:453-8.
11. Miyoshi A, Matsuo Y, Miwa T. Clinical effect of FRG-8813 (lafutidine) on gastritis: pilot study. Rinshouiyaku 1995;11:97-111.
12. Miyoshi A, Matsuo Y, Miwa T. Clinical dosage of FRG-8813 (lafutidine) on gastritis. Rinshouiyaku 1995;11:113-29.
13. Miyoshi A, Matsuo Y, Miwa T. Clinical evaluation of FRG-8813 (lafutidine) on gastritis. A double-blind comparative study versus cimetidine. Rinshouiyaku 1998;14:2121-38.
14. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole. Aliment Pharmacol Ther 1999;13(Suppl 3):27-36.
15. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996;60:661-6.
16. Isomoto H, Inoue K, Furusu H, Nishiyama H, Shikuwa S, Omagari K, Mizuta Y, Murase K, Murata I, Kohno S. Lafutidine, a novel histamine H2-receptor antagonist, versus lanso-prazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori. Helicobacter 2003;8:111-19.
17. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. Twelfth Informational Supplement M100-S12. Viillanova, PA: NCCLS, 2002.
18. Pounder RE. New developments in Helicobacter pylori eradication therapy. Scand J Gastroenterol Suppl 1997;223:43-5.
19. Cederbrant G, Kahlmeter G, Schalen C, Kamme C. Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori. J Antimicrob Chemother 1994;34:1025-9.
20. Gschwantler M, Dragosics B, Wurzer H, Brandstätter G, Weiss W. Eradication of Helicobacter pylori by a 1-week course of famotidine, amoxicillin and clarithromycin. Eur J Gastroenterol Hepatol 1998;10:579-82.
21. Gschwantler M, Dragosics B, Schutze K, et al. Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori-a randomized, controlled trial. Aliment Pharmacol Ther 1999;13:1063-9.
22. Graham DY, Hammoud F, El-Zimaity HM, Kim JG, Osato MS, El-Serag HB. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;17:1229-36.
23. Hsu CC, Chen JJ, Hu TH, Lu SN, Changchien CS. Famotidine versus omeprazole, in combination with amoxycillin and tinidazole, for eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2001;13:921-6.
24. Ell C, Schoerner C, Solbach W, Stolte M, Vieth M, Ridl W, Moser W, AMOR Study Group. The AMOR study: a randomized, double-blinded trial of omeprazole versus ranitidine together with amoxycillin and metronidazole for eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 2001;13:685-91.
25. Fujisawa T, Adachi K, Komazawa Y, Mihara T, Azumi T, Katsube T, Furuta K, Kazumori H, Kinoshita Y. Helicobacter pylori infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists. Aliment Pharmacol Ther 2004;20:559-65.
26. Kim N, Park SH, Seo GS, et al. Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus 2weeks for Helicobacter pylori eradication in Korea. Helicobacter 2008;13:542-9.